Clinically significant drug interactions with newer antidepressants (Q37968621)

26 August 2017

title

Clinically significant drug interactions with newer antidepressants (English)

1 reference

26 August 2017

1 reference

ChEBI release 2020-05-28

Edoardo Spina

1

1 reference

26 August 2017

Gianluca Trifirò

series ordinal

2

1 reference

26 August 2017

Filippo Caraci

series ordinal

3

1 reference

26 August 2017

publication date

1 January 2012

1 reference

26 August 2017

1 reference

26 August 2017

volume

26

1 reference

26 August 2017

issue

1

1 reference

26 August 2017

page(s)

39-67

1 reference

https://scigraph.springernature.com/pub.10.2165/11594710-000000000-00000

26 August 2017

exact match

0 references

cites work

World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for Biological Treatment of Unipolar Depressive Disorders in Primary Care

1 reference

https://api.crossref.org/works/10.2165%2F11594710-000000000-00000

Detrimental antidepressant drug-drug interactions: are they clinically relevant?

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11594710-000000000-00000

Pharmacokinetics of selective serotonin reuptake inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11594710-000000000-00000

Selective serotonin reuptake inhibitors and cytochrome P-450 mediated drug-drug interactions: an update

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11594710-000000000-00000

Clinically relevant pharmacokinetic drug interactions with second-generation antidepressants: an update

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11594710-000000000-00000

Metabolic drug interactions between antidepressants and anticancer drugs: focus on selective serotonin reuptake inhibitors and hypericum extract.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11594710-000000000-00000

SSRIs and upper gastrointestinal bleeding: what is known and how should it influence prescribing?

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11594710-000000000-00000

Inhibition of serotonin reuptake by antidepressants and upper gastrointestinal bleeding in elderly patients: retrospective cohort study

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11594710-000000000-00000

Association of risk of abnormal bleeding with degree of serotonin reuptake inhibition by antidepressants.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11594710-000000000-00000

Risk of upper gastrointestinal bleeding and the degree of serotonin reuptake inhibition by antidepressants: a case-control study

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11594710-000000000-00000

An association between selective serotonin reuptake inhibitor use and serious upper gastrointestinal bleeding.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11594710-000000000-00000

Association between selective serotonin reuptake inhibitors and upper gastrointestinal bleeding: population based case-control study.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11594710-000000000-00000

Use of selective serotonin reuptake inhibitors and risk of upper gastrointestinal tract bleeding: a population-based cohort study

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11594710-000000000-00000

Does concurrent prescription of selective serotonin reuptake inhibitors and non-steroidal anti-inflammatory drugs substantially increase the risk of upper gastrointestinal bleeding?

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11594710-000000000-00000

Combined use of SSRIs and NSAIDs increases the risk of gastrointestinal adverse effects

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11594710-000000000-00000

Selective serotonin reuptake inhibitors are associated with a modest increase in the risk of upper gastrointestinal bleeding

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11594710-000000000-00000

Selective serotonin reuptake inhibitors and the risk of stroke: a population-based case-control study

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11594710-000000000-00000

The use of antidepressants and the risk of haemorrhagic stroke: a nested case control study

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11594710-000000000-00000

Fluoxetine-warfarin interaction

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11594710-000000000-00000

Antidepressant interactions with warfarin

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11594710-000000000-00000

Fluvoxamine interaction with warfarin

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11594710-000000000-00000

Risk of clinically relevant bleeding in warfarin-treated patients--influence of SSRI treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11594710-000000000-00000

The effect of drug interactions on bleeding risk associated with warfarin therapy in hospitalized patients

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11594710-000000000-00000

Increased bleeding risk with concurrent use of selective serotonin reuptake inhibitors and coumarins

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11594710-000000000-00000

Antidepressants and risk of upper gastrointestinal bleeding

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11594710-000000000-00000

Interaction between selective serotonin reuptake inhibitors and nonsteroidal antiinflammatory drugs: review of the literature

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11594710-000000000-00000

Meta-analysis: gastrointestinal bleeding due to interaction between selective serotonin uptake inhibitors and non-steroidal anti-inflammatory drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11594710-000000000-00000

21 January 2018

The Serotonin Syndrome

1 reference

https://api.crossref.org/works/10.2165%2F11594710-000000000-00000

Coprescription of triptans with potentially interacting medications: a cohort study involving 240,268 patients

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11594710-000000000-00000

Evaluation of the potential pharmacokinetic interaction between almotriptan and fluoxetine in healthy volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11594710-000000000-00000

Clinical pharmacokinetics of frovatriptan

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11594710-000000000-00000

The serotonin syndrome, triptans, and the potential for drug-drug interactions

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11594710-000000000-00000

Pathophysiological role of the serotonin system in malignant hyperthermia

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11594710-000000000-00000

Serotonin toxicity and malignant hyperthermia: role of 5-HT2 receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11594710-000000000-00000

The FDA alert on serotonin syndrome with use of triptans combined with selective serotonin reuptake inhibitors or selective serotonin-norepinephrine reuptake inhibitors: American Headache Society position paper

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11594710-000000000-00000

Transporter-mediated drug interactions: clinical implications and in vitro assessment

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11594710-000000000-00000

Inhibition of P-glycoprotein by newer antidepressants

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11594710-000000000-00000

Venlafaxine induces P-glycoprotein in human Caco-2 cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11594710-000000000-00000

Escitalopram: a review of its use in the management of anxiety disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11594710-000000000-00000

Escitalopram: a review of its use in the management of major depressive disorder in adults

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11594710-000000000-00000

The clinical pharmacokinetics of escitalopram

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11594710-000000000-00000

The effect of cimetidine or omeprazole on the pharmacokinetics of escitalopram in healthy subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11594710-000000000-00000

Omeprazole preferentially inhibits the metabolism of (+)-(S)-citalopram in healthy volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11594710-000000000-00000

An evaluation of the potential for pharmacokinetic interaction between escitalopram and the cytochrome P450 3A4 inhibitor ritonavir

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11594710-000000000-00000

Non-response to citalopram in depressive patients: pharmacokinetic and clinical consequences of a fluvoxamine augmentation

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11594710-000000000-00000

Interaction between clonidine and escitalopram

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11594710-000000000-00000

Diphenhydramine alters the disposition of venlafaxine through inhibition of CYP2D6 activity in humans

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11594710-000000000-00000

Effect of ketoconazole on venlafaxine plasma concentrations in extensive and poor metabolisers of debrisoquine

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11594710-000000000-00000

Effect of venlafaxine on imipramine metabolism

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11594710-000000000-00000

Venlafaxine- and trazodone-induced serotonin syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11594710-000000000-00000

The effects of desvenlafaxine and paroxetine on the pharmacokinetics of the cytochrome P450 2D6 substrate desipramine in healthy adults

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11594710-000000000-00000

An assessment of drug-drug interactions: the effect of desvenlafaxine and duloxetine on the pharmacokinetics of the CYP2D6 probe desipramine in healthy subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11594710-000000000-00000

Duloxetine is both an inhibitor and a substrate of cytochrome P4502D6 in healthy volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11594710-000000000-00000

In vitro and in vivo evaluations of cytochrome P450 1A2 interactions with duloxetine

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11594710-000000000-00000

Effect of duloxetine on tolterodine pharmacokinetics in healthy volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11594710-000000000-00000

Comparison of duloxetine, escitalopram, and sertraline effects on cytochrome P450 2D6 function in healthy volunteers.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11594710-000000000-00000

Effect of adjunctive duloxetine on the plasma concentrations of clozapine, olanzapine, and risperidone in patients with psychotic disorders.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11594710-000000000-00000

Fluvoxamine augmentation increases serum mirtazapine concentrations three- to fourfold

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11594710-000000000-00000

Serotonin syndrome induced by fluvoxamine and mirtazapine

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11594710-000000000-00000

Drug-drug interaction studies with mirtazapine and carbamazepine in healthy male subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11594710-000000000-00000

Concomitant use of mirtazapine and phenytoin: a drug-drug interaction study in healthy male subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11594710-000000000-00000

Factors potentiating the risk of mirtazapine-associated restless legs syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11594710-000000000-00000

Effect of clopidogrel and ticlopidine on cytochrome P450 2B6 activity as measured by bupropion hydroxylation

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11594710-000000000-00000

Carbamazepine but not valproate induces bupropion metabolism.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11594710-000000000-00000

Cytochrome P450 2B6 activity as measured by bupropion hydroxylation: effect of induction by rifampin and ethnicity

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11594710-000000000-00000

Rapid clinical induction of hepatic cytochrome P4502B6 activity by ritonavir

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11594710-000000000-00000

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11594710-000000000-00000

Bupropion for major depressive disorder: Pharmacokinetic and formulation considerations

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11594710-000000000-00000

Nortriptyline toxicity secondary to interaction with bupropion sustained-release

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11594710-000000000-00000

Clinically relevant pharmacokinetic interaction between venlafaxine and bupropion: a case series

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11594710-000000000-00000

Severe sinus bradycardia after initiation of bupropion therapy: a probable drug-drug interaction with metoprolol

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11594710-000000000-00000

Interactions between tamoxifen and antidepressants via cytochrome P450 2D6.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11594710-000000000-00000

Escitalopram is a weak inhibitor of the CYP2D6-catalyzed O-demethylation of (+)-tramadol but does not reduce the hypoalgesic effect in experimental pain

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11594710-000000000-00000

Influence of comedication on serum concentrations of aripiprazole and dehydroaripiprazole

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11594710-000000000-00000

Interactions between herbal medicines and prescribed drugs: an updated systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11594710-000000000-00000

Lack of clinically significant interactions between concomitantly administered rasagiline and escitalopram

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11594710-000000000-00000

Venlafaxine extended-release: a review of its use in the management of major depression

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11594710-000000000-00000

Venlafaxine oxidation in vitro is catalysed by CYP2D6.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11594710-000000000-00000

O- and N-demethylation of venlafaxine in vitro by human liver microsomes and by microsomes from cDNA-transfected cells: effect of metabolic inhibitors and SSRI antidepressants

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11594710-000000000-00000

Venlafaxine metabolism as a marker of cytochrome P450 enzyme 2D6 metabolizer status.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11594710-000000000-00000

Venlafaxine: in vitro inhibition of CYP2D6 dependent imipramine and desipramine metabolism; comparative studies with selected SSRIs, and effects on human hepatic CYP3A4, CYP2C9 and CYP1A2.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11594710-000000000-00000

Role of CYP2D6 in the stereoselective disposition of venlafaxine in humans

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11594710-000000000-00000

Pharmacokinetic and pharmacodynamic evaluation of the potential drug interaction between venlafaxine and diazepam.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11594710-000000000-00000

CYP2D6 genotype, antidepressant use, and tamoxifen metabolism during adjuvant breast cancer treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11594710-000000000-00000

A case of serotonin syndrome caused by venlafaxine and lithium

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11594710-000000000-00000

Lithium and venlafaxine interaction: a case of serotonin syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11594710-000000000-00000

Risk of upper gastrointestinal tract bleeding associated with selective serotonin reuptake inhibitors and venlafaxine therapy: interaction with nonsteroidal anti-inflammatory drugs and effect of acid-suppressing agents

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11594710-000000000-00000

Gastro-intestinal haemorrhage risks of selective serotonin receptor antagonist therapy: a new look

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11594710-000000000-00000

Desvenlafaxine extended release

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11594710-000000000-00000

Desvenlafaxine: a new serotonin-norepinephrine reuptake inhibitor for the treatment of adults with major depressive disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11594710-000000000-00000

Duloxetine: a review of its use in the treatment of major depressive disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11594710-000000000-00000

Duloxetine: a review of its use in the treatment of generalized anxiety disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11594710-000000000-00000

Metabolism, excretion, and pharmacokinetics of duloxetine in healthy human subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11594710-000000000-00000

Duloxetine: clinical pharmacokinetics and drug interactions

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11594710-000000000-00000

The influence of smoking on the serum level of duloxetine

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11594710-000000000-00000

The effect of coadministration of duloxetine on steady-state serum concentration of risperidone and aripiprazole: a study based on therapeutic drug monitoring data

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11594710-000000000-00000

Effects of duloxetine on the pharmacodynamics and pharmacokinetics of warfarin at steady state in healthy subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11594710-000000000-00000

Milnacipran. A review of its use in depression

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11594710-000000000-00000

Milnacipran: beyond a role of antidepressant

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11594710-000000000-00000

Lack of interaction of milnacipran with the cytochrome p450 isoenzymes frequently involved in the metabolism of antidepressants

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11594710-000000000-00000

Lack of pharmacokinetic interaction when switching from fluoxetine to milnacipran

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11594710-000000000-00000

In vitro inhibition and induction of human liver cytochrome p450 enzymes by milnacipran.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11594710-000000000-00000

Mirtazapine: a review of its use in major depression and other psychiatric disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11594710-000000000-00000

Clinical pharmacokinetics of mirtazapine

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11594710-000000000-00000

Mirtazapine in combination with amitriptyline: a drug-drug interaction study in healthy subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11594710-000000000-00000

Mirtazapine and paroxetine: a drug-drug interaction study in healthy subjects.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11594710-000000000-00000

Lack of drug interactions between mirtazapine and risperidone in psychiatric patients: a pilot study

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11594710-000000000-00000

Lack of a pharmacokinetic interaction between mirtazapine and the newer antipsychotics clozapine, risperidone and olanzapine in patients with chronic schizophrenia.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11594710-000000000-00000

Steady-state concentrations of mirtazapine, N-desmethylmirtazapine, 8-hydroxymirtazapine and their enantiomers in relation to cytochrome P450 2D6 genotype, age and smoking behaviour.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11594710-000000000-00000

Serotonin syndrome produced by a combination of venlafaxine and mirtazapine

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11594710-000000000-00000

Severe serotonin syndrome induced by mirtazapine monotherapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11594710-000000000-00000

Mirtazapine-induced serotonin syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11594710-000000000-00000

Serotonin syndrome resulting from coadministration of tramadol, venlafaxine, and mirtazapine

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11594710-000000000-00000

Adverse reactions to mirtazapine are unlikely to be serotonin toxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11594710-000000000-00000

A review of serotonin toxicity data: implications for the mechanisms of antidepressant drug action

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11594710-000000000-00000

Mirtazapine abolishes hyperthermia in an animal model of serotonin syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11594710-000000000-00000

Restless legs syndrome as side effect of second generation antidepressants

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11594710-000000000-00000

The selective norepinephrine reuptake inhibitor antidepressant reboxetine: pharmacological and clinical profile.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11594710-000000000-00000

Clinical pharmacokinetics of reboxetine, a selective norepinephrine reuptake inhibitor for the treatment of patients with depression

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11594710-000000000-00000

No effect of reboxetine on plasma concentrations of clozapine, risperidone, and their active metabolites.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11594710-000000000-00000

The effects of reboxetine and amitriptyline, with and without alcohol on cognitive function and psychomotor performance

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11594710-000000000-00000

Noradrenergic adverse effects due to combined treatment with reboxetine and triiodothyronine

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11594710-000000000-00000

Bupropion: a review of its use in the management of major depressive disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11594710-000000000-00000

Inhibition of CYP2D6 activity by bupropion

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11594710-000000000-00000

Potent Mechanism-Based Inhibition of Human CYP2B6 by Clopidogrel and Ticlopidine

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11594710-000000000-00000

Selective inhibition of CYP2B6-catalyzed bupropion hydroxylation in human liver microsomes in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11594710-000000000-00000

An in vitro mechanistic study to elucidate the desipramine/bupropion clinical drug-drug interaction

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11594710-000000000-00000

A case of prolonged seizure activity after combined use of bupropion and clomipramine.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11594710-000000000-00000

The use of antidepressants in clinical practice: focus on agomelatine

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11594710-000000000-00000

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11594710-000000000-00000

Vilazodone, a novel dual-acting serotonergic antidepressant for managing major depression

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11594710-000000000-00000

Vilazodone: a 5-HT1A receptor agonist/serotonin transporter inhibitor for the treatment of affective disorders.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11594710-000000000-00000

Vilazodone: in major depressive disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11594710-000000000-00000

Antidepressant drugs: prevalence, incidence and indication of use in general practice of Southern Italy during the years 2003-2004.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11594710-000000000-00000

Antidepressant use in geriatric populations: the burden of side effects and interactions and their impact on adherence and costs.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11594710-000000000-00000

Antidepressants: clinically relevant drug interactions to be considered

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11594710-000000000-00000

Antidepressant-drug interactions are potentially but rarely clinically significant

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11594710-000000000-00000

Detecting drug interactions using personal digital assistants in an out-patient clinic

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11594710-000000000-00000

Pharmacology and pharmacokinetics of milnacipran

21 January 2018

2 references

https://api.crossref.org/works/10.2165%2F11594710-000000000-00000

21 January 2018

12 December 2020

Quantitative effect of CYP2D6 genotype and inhibitors on tamoxifen metabolism: implication for optimization of breast cancer treatment

1 reference

12 December 2020

Induction of drug efflux protein expression by venlafaxine but not desvenlafaxine

1 reference

12 December 2020

Seizure during combination of trimipramine and bupropion.

1 reference

12 December 2020

A pharmacokinetic drug-drug interaction study of venlafaxine and indinavir.

1 reference

12 December 2020

Warfarin-fluoxetine and diazepam-fluoxetine interaction

1 reference

12 December 2020

Lopinavir/ritonavir reduces bupropion plasma concentrations in healthy subjects

1 reference

12 December 2020

Agomelatine, the first melatonergic antidepressant: discovery, characterization and development

1 reference

12 December 2020

Hyponatremia associated with escitalopram

1 reference

12 December 2020

Pharmacokinetic drug interaction potential of selective serotonin reuptake inhibitors.

1 reference

12 December 2020

Transporter-mediated drug-drug interactions

1 reference

12 December 2020

Interaction of fluvoxamine with warfarin in an elderly woman.

1 reference

12 December 2020

Effects of venlafaxine treatment on clozapine plasma levels in schizophrenic patients

1 reference

12 December 2020

Venlafaxine and metabolites are very weak inhibitors of human cytochrome P450-3A isoforms

1 reference

12 December 2020

Serotonin syndrome associated with the use of escitalopram.

1 reference

12 December 2020

Concomitant use of mirtazapine and cimetidine: a drug-drug interaction study in healthy male subjects

1 reference

12 December 2020

The medical office of the 21st century (MOXXI): effectiveness of computerized decision-making support in reducing inappropriate prescribing in primary care.

1 reference

12 December 2020

Metabolism of the antidepressant mirtazapine in vitro: contribution of cytochromes P-450 1A2, 2D6, and 3A4

1 reference

12 December 2020

Effect of Terbinafine and Voriconazole on the Pharmacokinetics of the Antidepressant Venlafaxine

1 reference

12 December 2020

Orphenadrine and methimazole inhibit multiple cytochrome P450 enzymes in human liver microsomes

1 reference

12 December 2020

Cytochrome P-450-mediated metabolism of the individual enantiomers of the antidepressant agent reboxetine in human liver microsomes

1 reference

12 December 2020

[St. Johns wort-venlafaxine interaction]

1 reference

12 December 2020

Pharmacokinetics of milnacipran in comparison with other antidepressants

1 reference

12 December 2020

Effect of venlafaxine on the pharmacokinetics of risperidone.

1 reference

12 December 2020

Combining bupropion SR with venlafaxine, paroxetine, or fluoxetine: a preliminary report on pharmacokinetic, therapeutic, and sexual dysfunction effects

1 reference

12 December 2020

Escitalopram (S-citalopram) and its metabolites in vitro: cytochromes mediating biotransformation, inhibitory effects, and comparison to R-citalopram

1 reference

12 December 2020

Psychotropic interactions with warfarin

1 reference

12 December 2020

Low serum concentrations of reboxetine in 2 patients treated with CYP3A4 inducers

1 reference

12 December 2020

No effect of the new antidepressant reboxetine on CYP2D6 activity in healthy volunteers

1 reference

12 December 2020

Recognition and treatment of serotonin syndrome.

1 reference

12 December 2020

CYP2B6 mediates the in vitro hydroxylation of bupropion: potential drug interactions with other antidepressants.

1 reference

12 December 2020

Serotonergic and noradrenergic reuptake inhibitors: prediction of clinical effects from in vitro potencies.

1 reference

12 December 2020

Ketoconazole inhibits the clearance of the enantiomers of the antidepressant reboxetine in humans

1 reference

12 December 2020

Interaction of duloxetine and warfarin causing severe elevation of international normalized ratio

1 reference

12 December 2020

The influence of cimetidine on the disposition kinetics of the antidepressant venlafaxine

1 reference

12 December 2020

Effect of venlafaxine on CYP1A2-dependent pharmacokinetics and metabolism of caffeine

1 reference

12 December 2020

Effect of venlafaxine on the pharmacokinetics of alprazolam.

1 reference

12 December 2020

Desvenlafaxine and venlafaxine exert minimal in vitro inhibition of human cytochrome P450 and P-glycoprotein activities.

1 reference

12 December 2020

10.2165/11594710-000000000-00000

Identifiers

DOI

1 reference

Dimensions Publication ID

26 August 2017

1038171128

0 references

1 reference